- Home
- WDI vs STOK Comparison
WDI vs STOK Comparison
Compare WDI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- STOK
- Stock Information
- Founded
- WDI 2021
- STOK 2014
- Country
- WDI United States
- STOK United States
- Employees
- WDI N/A
- STOK N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- STOK Health Care
- Exchange
- WDI Nasdaq
- STOK Nasdaq
- Market Cap
- WDI 786.7M
- STOK 721.4M
- IPO Year
- WDI N/A
- STOK 2019
- Fundamental
- Price
- WDI $14.43
- STOK $11.68
- Analyst Decision
- WDI
- STOK Strong Buy
- Analyst Count
- WDI 0
- STOK 8
- Target Price
- WDI N/A
- STOK $21.83
- AVG Volume (30 Days)
- WDI 192.6K
- STOK 667.4K
- Earning Date
- WDI 01-01-0001
- STOK 11-05-2024
- Dividend Yield
- WDI 11.80%
- STOK N/A
- EPS Growth
- WDI N/A
- STOK N/A
- EPS
- WDI 1.12
- STOK N/A
- Revenue
- WDI N/A
- STOK $16,742,999.00
- Revenue This Year
- WDI N/A
- STOK $103.66
- Revenue Next Year
- WDI N/A
- STOK N/A
- P/E Ratio
- WDI $12.82
- STOK N/A
- Revenue Growth
- WDI N/A
- STOK 81.08
- 52 Week Low
- WDI $12.16
- STOK $4.09
- 52 Week High
- WDI $14.69
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- WDI 32.98
- STOK 44.25
- Support Level
- WDI $14.84
- STOK $10.61
- Resistance Level
- WDI $15.03
- STOK $12.58
- Average True Range (ATR)
- WDI 0.19
- STOK 0.95
- MACD
- WDI -0.06
- STOK -0.12
- Stochastic Oscillator
- WDI 19.35
- STOK 28.34
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.